Industry News
Biotechnology Industry News
AAIC 2025 spotlights inflammation…
AAIC 2025 spotlights inflammation in Alzheimer’s; InMed’s INM-901 reduces key biomarkers linked to disease progression
Arthrosi Therapeutics has raised…
Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3 trials next year.
In a pair of deals, TransCode has…
In a pair of deals, TransCode has bagged a phase 3 cancer vaccine and a $25 million injection into its cash-strapped coffers.
Nilo Therapeutics has launched…
Nilo Therapeutics has launched with $101 million in series A funds to drive its ambition to harness neural circuits to restore immune homeostasis.
Sanofi’s $110 million bet on a…
Sanofi’s $110 million bet on a radioligand seems to be paying off after the neuroendocrine tumor treatment hit the key endpoints of a phase 2 study.
Six months after his departure…
Six months after his departure from the federal government, Peter Marks, M.D., Ph.D., has joined Eli Lilly.
The financing will help Kernal…
The financing will help Kernal advance its early-stage program KR-402 through clinical development in multiple sclerosis and B-cell malignancies.
A new RNA biotech has risen with a…
A new RNA biotech has risen with a $200 million series A in the tank and a team of seasoned biotech chefs ready to light the burners. Soufflé Therapeutics will cook up siRNA medicines that
PFAS’s environmental persistence…
PFAS's environmental persistence and health risks are prompting regulations impacting medical devices. Discover key insights and solutions from the experts at Battelle.
GLD Partners has secured access to…
GLD Partners has secured access to Heligenics’ GigaAssay platform to launch Altagenics, a startup with ambitions to develop first-in-class medicines for muscle-wasting conditions.
Clinical setbacks and…
Clinical setbacks and controversial pricing may have put a dampener on the gene therapy sector, but one of the industry’s pioneers is looking for a way forward.
MapLight is hoping to raise up to…
MapLight is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy.
AstraZeneca has hailed another…
AstraZeneca has hailed another phase 3 win for its blood pressure drug candidate baxdrostat, boosting its attempts to turn the molecule’s long half-life into a competitive advantage.
Bicoastal life sciences investment…
Bicoastal life sciences investment firm TCG Crossover (TCGX) has closed its third fund in about four years, securing $1.3 billion to bring its total capital raised to $3.1 billion.
Skye Bioscience’s obesity…
Skye Bioscience’s obesity candidate has failed to reduce weight in a phase 2 study, marking another setback for the CB1 inhibitor class.
AstraZeneca has signed a $555…
AstraZeneca has signed a $555 million deal with San Francisco biotech Algen Biotechnologies that will tap the latter company’s artificial intelligence platform to boost discovery of new targets in immunology.
AbbVie has warned investors that…
AbbVie has warned investors that it expects to take a $2.7 billion hit tied to acquired in-process research and development expenses and milestones in the third quarter.
Ignota Labs has harvested more…
Ignota Labs has harvested more assets for its drug candidate rehabilitation scheme, snapping up Kronos Bio’s clinical pipeline months after a series of setbacks drove the biotech off public markets.
Biopharmas recorded 62 layoff…
Biopharmas recorded 62 layoff rounds, just a smidge lower than the 64 reported both in the first and second quarter each, according to Fierce Biotech’s Layoff Tracker.
A few months after launching its…
A few months after launching its lead gene therapy into the clinic, Arbor Biotechnologies has found a European partner to come along for the ride.